0001415889-24-016208.txt : 20240610 0001415889-24-016208.hdr.sgml : 20240610 20240610162110 ACCESSION NUMBER: 0001415889-24-016208 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240606 FILED AS OF DATE: 20240610 DATE AS OF CHANGE: 20240610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gallagher Carol Giltner CENTRAL INDEX KEY: 0001329959 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39539 FILM NUMBER: 241033028 MAIL ADDRESS: STREET 1: C/O ATARA BIOTHERAPEUTICS, INC. STREET 2: 3260 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PMV Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001699382 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 463218129 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE RESEARCH WAY CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 642-6664 MAIL ADDRESS: STREET 1: ONE RESEARCH WAY CITY: PRINCETON STATE: NJ ZIP: 08540 4 1 form4-06102024_080606.xml X0508 4 2024-06-06 0001699382 PMV Pharmaceuticals, Inc. PMVP 0001329959 Gallagher Carol Giltner C/O PMV PHARMACEUTICALS, INC. 1 RESEARCH WAY PRINCETON NJ 08540 true false false false 0 Stock Option (right to buy) 1.65 2024-06-06 4 A 0 67500 0 A 2034-06-05 Common Stock 67500 67500 D Stock Option (right to buy) 1.65 2024-06-07 4 G 0 67500 0 D 2034-06-05 Common Stock 67500 0 D Stock Option (right to buy) 1.65 2024-06-07 4 G 0 67500 0 A 2034-06-05 Common Stock 67500 67500 I See footnote The option vests as follows: 22,500 shares vest on the earlier of (i) June 6, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders and the remaining 45,000 shares vest in 36 equal monthly installments beginning on July 6, 2024. The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee. /s/ Robert Ticktin, by power of attorney 2024-06-10 EX-24 2 ex24-06102024_080606.htm OMB APPROVAL



POWER OF ATTORNEY


The undersigned, as a Section 16 reporting person of PMV Pharmaceuticals, Inc. (the “Company”), hereby constitutes and appoints David H. Mack, Ph.D., Robert Ticktin, and Michael Carulli, and each of them, as the undersigned’s true and lawful attorney-in-fact to:


1.

prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the Securities and Exchange Commission (the “SEC”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain EDGAR codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;


2.

complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned’s ownership, acquisition or disposition of securities of the Company; and


3.

do all acts necessary in order to file such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.


The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof.  The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).


This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.


IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 5th day of January, 2024.



Signature: /s/ Carol Gallagher


Print Name:  Carol Gallagher, Pharm.D.